Embodiments include an apparatus comprising a frequency selective electromagnetic receiver and a signal analyzing module. The frequency selective electromagnetic receiver is configured to receive a reradiating electromagnetic signal resulting from a cavity induced modulation phenomenon occurring within cavit(ies). The signal analyzing module is configured to: determine a power spectral density of the reradiating electromagnetic signal. Frequencies are observed at which the amplitude modulation of the power spectral density peaks. A cavity length is determined employing the frequencies of the power spectral density peaks.
G01S 13/34 - Systèmes pour mesurer la distance uniquement utilisant la transmission d'ondes continues, soit modulées en amplitude, en fréquence ou en phase, soit non modulées utilisant la transmission d'ondes continues modulées en fréquence, tout en faisant un hétérodynage du signal reçu, ou d’un signal dérivé, avec un signal généré localement, associé au signal transmis simultanément
G01S 13/88 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques
G01S 5/02 - Localisation par coordination de plusieurs déterminations de direction ou de ligne de positionLocalisation par coordination de plusieurs déterminations de distance utilisant les ondes radioélectriques
An attention assistance device for providing attention assistance including various features that help maintain a user's focus on a given task. The attention assistance device may include an activity sensor that generates an activity output in response to detection of a user generated activity. The attention assistance device may also have a timer that increments a counter at regular time intervals, resets the counter in response to the activity output, and generates a timer output when the counter reaches a threshold. Further, the attention assistance device may include a stimulation unit that alerts a user in response to the timer output.
An attention assistance device configured to help maintain a user's focus on a given task. In one embodiment, text is presenting to a user on a touchscreen. The user tracking the text using a finger is monitored. The user is stimulated when the finger stops tracking the text for a predetermined period of time. In another embodiment, an electronic device presents an output configured to be tracked by a user. A monitoring device observes the user tracking the output. A sensory stimulating device stimulates the user when the “tracking” falls below an attention threshold.
[0082] In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits l-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).
A01N 57/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques du phosphore comportant des liaisons phosphore-carbone
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
The United States of America, as represented by the Secretary of Commerce (USA)
The National Institute of Standards and Technology (USA)
George Mason Intellectual Properties, Inc. (USA)
Inventeur(s)
Jajodia, Sushil
Wang, Lingyu
Noel, Steven
Singhal, Anoop
Abrégé
Systems and methods for determining a safety level of a network vulnerable to attack from at least one origin to at least one target are described. Machines, components, and vulnerabilities in a network may be associated to one another. Degrees of similarity among the vulnerabilities may be determined and subsets of vulnerabilities may be grouped based on their determined degrees of similarity to one another. This data may be used to generate an attack graph describing exploitation of vulnerabilities and grouped vulnerabilities and defining vulnerability exploit condition relationships between at least one origin and at least one target. The attack graph may be analyzed using a k-zero day metric function to determine a safety level.
G06F 21/00 - Dispositions de sécurité pour protéger les calculateurs, leurs composants, les programmes ou les données contre une activité non autorisée
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
H04L 29/06 - Commande de la communication; Traitement de la communication caractérisés par un protocole
Disclosed is a system for correlating intrusion events using attack graph distances. The system includes an attack graph generator, an exploit distance calculator, an intrusion detector, an event report/exploit associator, an event graph creator, an event graph distance calculator, a correlation value calculator, and a coordinated attack analyzer. An attack graph is constructed for exploits and conditions in a network. The exploit distance calculator determines exploit distances for exploit pair(s). The intrusion detector generates event. Events are associated with exploits. Event graph distances are calculated. Correlation values are calculated for event pair(s) using event graph distances. The correlation values are analyzed using a correlation threshold to detect coordinated attacks.
Embodiments locate a botmaster on a network. A honeynet host is configured to join a botnet and generate a watermarked packet flow by applying a watermark to an outgoing packet flow in response to commands from the botmaster. The watermark is applied to the outgoing packet flow by: choosing distinct packets from the outgoing packet flow; forming packet pair(s) from the distinct packets, that include a reference packet and an encoding packet; and encoding bits in the watermark to the packet pair(s) by increasing the length of the encoding packet when watermark bits have a predetermined value. The cooperating node(s) are configured to: inspect passing packet flows for the watermarked packet flow and generate tracking information related to detection of the watermarked packet flow. The path determination processor is configured to analyze the tracking information to locate a path taken by the watermarked packet flow.
G06F 15/173 - Communication entre processeurs utilisant un réseau d'interconnexion, p. ex. matriciel, de réarrangement, pyramidal, en étoile ou ramifié
An attention assistance device configured to help maintain a user's focus on a given task. In one embodiment, text is presenting to a user on a touchscreen. The user tracking the text using a finger is monitored. The user is stimulated when the finger stops tracking the text for a predetermined period of time. In another embodiment, an electronic device presents an output configured to be tracked by a user. A monitoring device observes the user tracking the output. A sensory stimulating device stimulates the user when the “tracking” falls below an attention threshold.
An apparatus for detecting a cavity comprising a signal receiver, a signal analyzer and a threshold excedent determination processor. The signal receiver receives a reflected signal resulting from an interaction of multi-frequency irradiating signal(s) with at least one cavity. The irradiating signal may include an electromagnetic or acoustic signal above a cavity dependent cutoff frequency with a randomized spectral component. The signal analyzer computes cavity detecting statistic(s) of the reflected signal. The cavity detecting statistic(s) may include an autocorrelation function. The autocorrelation function may be a Fourier transform of the power spectral density of the reflected signal. The threshold excedent determination processor generates a notification when cavity detecting statistic(s) exceed a threshold. The threshold may include a multi-variable function. The cavity may be the bore of a weapon. The apparatus may be configured to determine the bearing from the cavity to the apparatus.
The invention relates to a one-step chemical composition that preserves animal tissue, cells, and biomolecules, such as human tissue, human cells, and biomolecules therein. It improves the fidelity and morphologic structure of cells, organelles, and nuclear chromatin, and maintains and enhances the cellular antigenicity for immunohistochemistry and flow cytometry, while preserving proteins, post-translational modifications of proteins, and nucleic acids. In one embodiment, the composition comprises a) a non-aldehyde precipitating fixative at a concentration below 25% (volume/volume), b) a reversible/cleavable protein cross-linker that targets lipid-associated molecules, and c) a c reversible/cleavable protein cross-linker that targets water soluble molecules. In another embodiment, the composition further includes a kinase inhibitor, a phosphatase inhibitor, and a permeation enhancer. In still another embodiment, the compositions further include lactic acid at a concentration sufficient to maintain cellular nuclear volume at a level equivalent to aldehyde fixation of the same type of cell. In a further embodiment, the composition comprises: a) a precipitating fixative, b) a reversible/cleavable cross-linker, c) a permeation enhancer, d) a kinase inhibitor, e) a phosphatase inhibitor, and f) a carboxylic acid. In a still further embodiment, the invention comprises method for preserving a biological sample by contacting the sample with the composition of the invention under conditions effective for the preservation of the sample.
A method for determining the suitability of a biological sample. A diagnostic value is determined by measuring diagnostic peptide analytes from a biological sample. A normalization value is determined by measuring normalization analytes from a biological sample. The suitability score is determined by comparing the diagnostic value to the normalization value such that the combination of the normalization allied meets a preselected level of precision.
An attention assistance device for providing attention assistance including various features that help maintain a user's focus on a given task. The attention assistance device may include an activity sensor that generates an activity output in response to detection of a user generated activity. The attention assistance device may also have a timer that increments a counter at regular time intervals, resets the counter in response to the activity output, and generates a timer output when the counter reaches a threshold. Further, the attention assistance device may include a stimulation unit that alerts a user in response to the timer output.
An egocentric display that corresponds to a multidimensional frame of reference. The multidimensional frame of reference may include an ego center, a nadir below the ego center, and a zenith above the ego center. The egocentric display includes a center point, an inner concentric circle and an outer concentric circle. The center point represents the nadir. The inner concentric circle is centered about the center point and represents a horizon plane that is perpendicular to a zenith-nadir line that passes through the zenith, the ego center, and the nadir. The outer concentric circle that represents the zenith should have a radius larger that the inner concentric circle and should also be centered about the center point.
G09G 5/00 - Dispositions ou circuits de commande de l'affichage communs à l'affichage utilisant des tubes à rayons cathodiques et à l'affichage utilisant d'autres moyens de visualisation
REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE (USA)
Inventeur(s)
Mueller, Claudius
Liotta, Lance
Schrag, Matthew
Kirsch, Wolff, M.
Vinters, Harry, V.
Abrégé
Methods and kits for identifying and/or monitoring neurological conditions in a patient using ratios of biomarkers are disclosed. The neurological conditions may include, for example, Alzheimer's disease or mild cognitive impairment. The particular biomarkers that may be useful in identifying and/or monitoring neurological conditions may include, for example, biliverdin reductase, biliverdin reductase, estrogen receptor alpha, superoxide dismutase, S100A7, hemeoxygenase 1, matrix metalloproteinase 9 and platelet derived growth factor receptor. In particular, ratios of these biomarkers are useful.
Disclosed is a system for modeling, analyzing, and responding to network attacks. Machines are mapped to components, components are mapped to vulnerabilities, and vulnerabilities are mapped to exploits. Each of the exploits includes at least one precondition mapped to at least one postcondition. An attack graph which defines inter-exploit distances is generated using at least one of the exploits. The attack graph is aggregated. At least one hardening option is determined using the aggregated attack graph. Hardening options include applying at least one corrective measure to at least one initial condition, where the initial condition is the initial state of a precondition.
A service-oriented system architecture includes a computer-implemented search method and computer-implemented agent system for enabling efficient information searches on, for example, on XML databases, relational databases, and files located on intranets, the Internet, or other computer network systems. Referred to as the Knowledge Sifter architecture, the architecture may comprise, in one embodiment, a community of cooperating agents. The system architecture may be employed using a variety of methodologies, such as a case-based framework, collaborative filtering, or hybrid filtering. The case-based framework may be configured to recommend query specifications and refinements based on previously-stored user-query cases. Collaborative filtering involves the architecture recommending a set of unseen items that are preferred by other users to the active user. Hybrid filtering combines collaborative filtering and content-based filtering.
Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 31/00 - Recherche ou analyse des matériaux non biologiques par l'emploi des procédés chimiques spécifiés dans les sous-groupesAppareils spécialement adaptés à de tels procédés
19.
ANTIMICROBIAL AND ANTIBIOFILM ACTIVITY OF CATHELICIDINS
The present disclosure relates to peptides, and fragments thereof, conferring antimicrobial and/or antibiofilm growth, as well as products and methodology for using same.
Described herein are progenitor cancer cells and cell lines isolated from human breast ductal carcinoma in situ (DCIS) lesions and the uses of these cells or cell lines in drug design, drug screening, and monitoring in vivo therapy. The DCIS malignant precursor cells or cell lines are epithelial in origin, are positive for markers of autophagy, show at least one genetic difference from normal cells of said fragment, form 3-D tube-like structures or ball aggregates, or are inhibited in formation of 3-D structures and migration by treatment with chloroquine.
Alkalinity determination, including an alkalinity determination process and/or alkalinity determinator. An alkalinity determination process may include providing a known value of volume of an acidic fluid, forming a titration system by providing one or more additions of a known value of volume of a relatively alkaline fluid to an acidic fluid, determining a pH value and/or a temperature value for one or more additions and/or determining an alkalinity value of a system by calculating a transformation including one or more determined pH values and/or temperature values of one or more additions. An alkalinity determination process may include modeling, such that an informed determination may be made with reference to relevant and/or irrelevant factors, as well as parameters to maximize likelihood of alkalinity determination. In embodiments, an alkalinity determinator may include one or more titration cells, one or more sensors and/or one or more alkalinity value determinators.
G01N 31/18 - Burettes spécialement adaptées pour le titrage
G01N 31/00 - Recherche ou analyse des matériaux non biologiques par l'emploi des procédés chimiques spécifiés dans les sous-groupesAppareils spécialement adaptés à de tels procédés
G01N 25/00 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques
G01N 25/20 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la production de quantités de chaleur, c.-à-d. la calorimétrie, p. ex. en mesurant la chaleur spécifique, en mesurant la conductivité thermique
A cache validating SCIT-DNS Server including a server cluster, a cache copy, a controller and a validation module. Each of the servers in the server cluster uses a DNS mapping cache which maps DNS name(s) to record entry(ies). The cache copy maintains an image of DNS mapping cache(s). The controller manages the state of servers. States include a live spare state; an exposed state; a quiescent state; and a self-cleansing state. The validation module validates DNS entry(s) using a retriever module and a comparisons module. Retriever module retrieves an independent record entry associated with a selected DNS name from an external DNS resolver. The comparison module compares the independent record entry retrieved by the retriever module with the record entry associated with the selected DNS name residing in the cache copy. The validation module may cause server(s) to take an affirmative action in response to detected validation error(s).
G06F 15/173 - Communication entre processeurs utilisant un réseau d'interconnexion, p. ex. matriciel, de réarrangement, pyramidal, en étoile ou ramifié
23.
System and method for analyzing the structure of logical networks
Systems and methods for analyzing the structure of logical networks. Embodiments of the invention include ranking critical nodes according to regional hierarchies, distance hierarchies, global hierarchies, and relay hierarchies. Embodiments of the present invention are capable of testing the effectiveness of such hierarchies. In addition, critical nodes may be used to define critical regions.
G06F 15/173 - Communication entre processeurs utilisant un réseau d'interconnexion, p. ex. matriciel, de réarrangement, pyramidal, en étoile ou ramifié
H04L 12/28 - Réseaux de données à commutation caractérisés par la configuration des liaisons, p. ex. réseaux locaux [LAN Local Area Networks] ou réseaux étendus [WAN Wide Area Networks]
A wearable decorative ornament capable of photographing, storing and displaying an image, such that the image appears integral to the design of the decorative ornament, comprising a decorative case, an image-displaying device, an image capturing device, a communications port and a controller.
Disclosed is a self-cleansing intrusion tolerance-domain name systems system comprising at least three DNS servers, at least four storage systems accessible by the DNS servers, a communications link, a message transfer mechanism, and a self-cleansing mechanism. The storage systems include at least three online storage systems and at least one offline storage system. The communications link can connect the DNS servers with the storage systems, as well as connect the DNS servers with a local area network, which can connect the DNS servers with an external network. The message transfer mechanism can rotate the DNS servers into a plurality of roles, including a primary role, a secondary role, a designated role, and a self-cleansing role. The self-cleansing mechanism can be used to perform the self-cleansing role.
G06F 15/16 - Associations de plusieurs calculateurs numériques comportant chacun au moins une unité arithmétique, une unité programme et un registre, p. ex. pour le traitement simultané de plusieurs programmes
A multidimensional sensor data analyzer that includes: discretizing values in multidimensional sensor data at index locations in value surfaces that reside in a multidimensional value space; deriving surface components resulting from the intersection of a geometric beam shape function that describing the sensor beam with the value surfaces; determining minimum-maximum index location limits for the surface components; determining surface component index points by identifying the index locations that are located within the minimum-maximum index location limits for the surface components; and generating a beam value by performing a beam function using the values at the surface component index points.
A system and method for processing a client request using single use virtual servers. The method: receives the client request from a network; passes the client request to a new virtual incoming client request server; passes an application request from the virtual incoming client request server to a new virtual application server; destroys the virtual incoming client request server; passes an application result from the virtual application server to a new virtual outgoing client result server; destroys the new virtual application server; passes the application result from the new virtual outgoing client request server to the network; and destroys the virtual outgoing client request server.
G06F 15/16 - Associations de plusieurs calculateurs numériques comportant chacun au moins une unité arithmétique, une unité programme et un registre, p. ex. pour le traitement simultané de plusieurs programmes
G06F 15/173 - Communication entre processeurs utilisant un réseau d'interconnexion, p. ex. matriciel, de réarrangement, pyramidal, en étoile ou ramifié
A nanowire field effect junction diode constructed on an insulating transparent substrate that allows form(s) of radiation such as visual light, ultraviolet radiation; or infrared radiation to pass. A nanowire is disposed on the insulating transparent substrate. An anode is connected to a first end of the nanowire and a cathode is connected to the second end of the nanowire. An oxide layer covers the nanowire. A first conducting gate is disposed on top of the oxide layer adjacent with a non-zero separation to the anode. A second conducting gate is disposed on top of the oxide layer adjacent with a non-zero separation to the cathode and adjacent with a non-zero separation the first conducting gate. A controllable PN junction may be dynamically formed along the nanowire channel by applying opposite gate voltages. Radiation striking the nanowire through the substrate creates a current the anode and cathode.
A multidimensional sensor data analyzer that includes: discretizing values in multidimensional sensor data at index locations in value surfaces that reside in a multidimensional value space; deriving surface components resulting from the intersection of a geometric beam shape function that describing the sensor beam with the value surfaces; determining minimum-maximum index location limits for the surface components; determining surface component index points by identifying the index locations that are located within the minimum-maximum index location limits for the surface components; and generating a beam value by performing a beam function using the values at the surface component index points.
This invention relates generally to a treatment of cancer and more particularly to the identification of carcinomas that are likely to respond to an inhibitor of the ERBB family pathway in the carcinoma cells and to the treatment of patients having such carcinomas with such inhibitors. The invention includes, but is not limited to: 1) a method of determining if a carcinoma in a mammal is likely to respond to an ERBB family pathway inhibitor; 2) a method of treating the mammal with an ERBB family pathway inhibitor; 3) a method for identifying such inhibitors; and 4) a kit for use in such assay.
Methods of selecting a treatment for a patient with multiple myeloma are provided. Prior to commencing a treatment regime, bone marrow aspirates are isolated from a patient and incubated with one or more candidate therapeutics. The methods identify the therapy or combination of therapies most likely to yield the best results for a particular individual. In addition to improving clinical outcome, such theranostic evaluations dramatically reduce health care costs, by avoiding ineffective therapies. Screening assays for identifying treatments for multiple myeloma also are provided.
A process of removing viruses from drinking water is disclosed. The process involves filtering drinking water, having a viral contaminant, through a layer of coarse sand; contacting the drinking water with a composite iron matrix; and purifying the drinking water by allowing the composite iron matrix to adsorb the viral contaminant for at least fifteen minutes. The major component of the composite iron matrix is an iron component, which is at least about 68% to about 92% iron by weight. Other components include manganese; cerium; carbon; phosphorous; sulfur; aluminum; silicon; chromium; copper; and zinc.
The present invention relates to the identification and diagnostic use of biomarkers in primary colorectal cancer tumors whose activation level are predictive of the likelihood of the onset of metastatic disease. These biomarkers may be used to determine the suitability of a patient for aggressive and/or targeted treatments. Kits and compositions of the invention are also provided.
The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.
The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.
This invention provides a method of producing cyathin A3 in a culture of Cyathus helenae. It employs added bacteria to stimulate production of cyathin A3.
This invention relates, e.g., to a method for identifying a class of subjects having MLL who are likely to be responsive to treatment with an inhibitor of a member of the AMPK signaling pathway. The method comprises measuring the amount of phosphorylation at particular residues of members of the AMPK signal transduction pathway, e.g. residues S428 of LKB l, S485 of AMPKα, S108 of AMPKβ, and/or Sl 16 of eNOS III, in a sample from the subject, wherein a significantly elevated level of phosphorylation at one or more of the residues compared to a baseline value indicates that the subject is likely to be responsive to treatment with an inhibitor of a member of the AMPK signaling pathway. In one embodiment of the invention, a subject which is determined to be likely to responsive to treatment with an inhibitor of a member of the AMPK signaling pathway, by a method as above, is administered an effective amount of an inhibitor of production or activity of one or more of the phosphoproteins of the signaling pathway.
G01N 33/567 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand utilisant un extrait de tissu ou d'organe comme agent de liaison
38.
Wireless communications using frequency agile radio
A frequency agile radio configured to determine an estimated coverage area of a primary transmitter is disclosed. The radio includes at least one position device configured to determine a position coordinate of the radio and generate a corresponding position signal. The radio also includes at least one frequency agile receiver configured to measure a power of a transmission at least one frequency and generate a corresponding signal. Additionally, the radio includes at least one controller in communication with the at least one position device and the at least one frequency agile receiver. The controller is configured to determine a plurality of position coordinates of the radio and a plurality of signal power datums. The controller is also configured to estimate the coverage area of the at least one primary transmitter, based on the determined plurality of position coordinates and the determined plurality of signal power datums.
To preprocess a tissue sample, a first permeable mesh membrane is tautly stretched out over the tissue sample and overlaid on top of a flat surface. This covering sandwiches and secures the tissue sample in between the first permeable mesh membrane and the flat surface. If it is desired to reinforce the mechanical strength of the first permeable mesh membrane, a second permeable mesh membrane can be tautly stretched out and overlaid on top of the sandwich. Alternatively, the second permeable mesh membrane can be attached onto a third component, such as a disposable solvent resistant frame, to create a framed mesh. Thereafter, the first permeable mesh membrane may be attached to the framed mesh to create a compound framed mesh. The tissue sample may then be sandwiched and secured in between the compound framed mesh and the flat surface. To retain and flatten the tissue sample, gentle pressure may be uniformly applied.
Disclosed is a self-cleansing system comprising at least two subsystems including an active subsystem and at least one available inactive subsystem. At least two of the subsystems may be connected to each other by a communications link and connected to an external network through a local network. An arbitration mechanism is capable of designating one of the at least one available inactive subsystem to be a designated active system. An active subsystem and a designated active subsystem may share an IP address, but only the active subsystem utilizes the IP address to output information to the external network. A transfer mechanism capable of deactivating the active subsystem and then activating a designated active system may be initiated by a transfer criterion. A self-cleansing mechanism may then cleanse the deactivated subsystem.
G06F 11/00 - Détection d'erreursCorrection d'erreursContrôle de fonctionnement
G06F 12/16 - Protection contre la perte de contenus de mémoire
G06F 15/18 - dans lesquels un programme est modifié en fonction de l'expérience acquise par le calculateur lui-même au cours d'un cycle complet; Machines capables de s'instruire (systèmes de commande adaptatifs G05B 13/00;intelligence artificielle G06N)
G08B 23/00 - Alarmes réagissant à des conditions indésirables ou anormales, non spécifiées
41.
Tailoring medication to individual characteristics
Disclosed is a medical outcome prediction tool that predicts an individual patient's medical outcomes by identifying patients having a same disease; selecting a set of characteristics unique to an individual; determining the similarities between the individual and other cases; and calculating the expected outcome for the individual that is proportional to a weighted sum of outcomes of similar cases. The similarities can be determined by calculating the number of matches between the individual and cases over the set of characteristics, and using that result to determine a similarity score.
This invention relates, e.g., to a set of calibrants for determining the amount in a sample of an analyte (e.g., a protein, such as a protein that has been post-translationally modified), comprising a plurality of calibrants, which contain a range of amounts (e.g., defined amounts and/or serial dilutions) of the analyte, spanning the expected amount of the analyte in the sample. In each of the calibrants, a defined amount of the analyte is present in the same suitable, biological diluent (e.g., a cell or tissue lysate, or a bodily fluid). In one embodiment of the invention, the diluent reflects the same or a similar biological milieu (proteins, lipids, serum proteins, serum matrix proteins, etc.) as that in the sample in which the analyte to be measured is present. In embodiments of the invention, a single calibrant (e.g., a cell lysate) may comprise as many as hundreds of analytes, and can be used for the quantification of those hundreds of analytes in a sample. Methods are described for performing an assay (e.g. RPMA analysis), in which the calibrants of a set of calibrants of the invention are immobilized on each of the surfaces to which samples to be analyzed are immobilized, thereby providing an internal calibration curve for quantifying an RPMA assay.
G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
This invention relates, e.g., to a method for predicting the response of a subject having, or at risk of developing, breast cancer to Tamoxifen therapy. The method comprises measuring the amount of phosphorylation at residues S70 of Bcl-2, Y992 of EGFR, and/or Y527 of Src in a suitable sample from the subject, wherein a statistically significantly elevated level of phosphorylation at one or more of the three residues compared to a baseline value indicates that the subject is likely to be responsive to Tamoxifen therapy.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
44.
METHODS OF DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods.
A subject's likelihood of responding to bariatric surgery can be assessed by measuring the phosphorylation state of certain proteins found in white adipose tissue (WAT). In particular, measuring the phosphorylation state of particular proteins can predict a patient's likelihood of resolving diabetes mellitus following bariatric surgery. In addition, evaluating the phosphorylation state of certain proteins forecasts a patient's capacity to reduce excess body weight and/or waist size following bariatric surgery. Such tests are valuable tools for managing the diseases of diabetes and obesity and determining who would most likely benefit from bariatric surgical procedures such as gastic bypass surgery.
This invention relates, e.g., to a method for predicting the response of a subject having estrogen-receptor-positive breast cancer to an inhibitor of the estrogen signaling pathway (e.g. tamoxifen), comprising measuring in a cancer sample from the subject the level of phosphorylation, compared to a baseline value, of one or more of the following members of an interconnected intracellular signaling pathway: (a) 4EBP 1, and/or (b) p70S6, and/or (c) STAT3, and/or (d) FAK, wherein a significantly elevated level of phosphorylation of 4EBP1, and/or p70S6 and/or STAT3, and/or a significantly decreased level of phosphorylation of FAK, compared to the baseline value, indicates that the subject is likely to be a non-responder to the inhibitor and/or has a poor prognosis. Additional members of the intracellular signaling pathway whose phosphorylation can be measured are also described. Also described is a method for treating breast cancer in a subject in need thereof, wherein the subject exhibits an elevated level of phosphorylation of these markers, comprising administering to the subject an effective amount of one or more inhibitors of members of the interconnected intracellular signaling pathway.
An iron composition having a plurality of elemental components is disclosed. The major component is an iron component of at least about 68% to about 92% iron by weight. Other components by weight include manganese; cerium; carbon; phosphorous; sulfur; aluminum; silicon; chromium; copper; and zinc. Combined with layers of sand, brick chips and/or charcoal, the iron composition can be used to create a water filter for filtering inorganic arsenic species and soluble metal ions out of water. To enhance hydrous ferric oxide complexation and precipitation, the iron composition may be treated with food grade acids or a water mixture.
B01D 15/00 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solidesAppareillages pour ces procédés
B01J 39/00 - Échange de cationsUtilisation d'une substance comme échangeur de cationsTraitement d'une substance en vue d'améliorer ses propriétés d'échange de cations
An interval centroid-based watermark encoder encodes a watermark into a packet flow. Intervals are defined for the packet flow. Some of the intervals are selected as group A intervals while other intervals are selected as group B intervals. Group A and group B intervals are paired and assigned to watermark bits. A first or second value may be encoded by increasing the relative packet time between packets in either the group A (for the first bit value) or group B (for the second bit value) interval(s) of the interval pair(s) assigned to the watermark bits that are to represent the first or second bit value and the beginning of the same group interval(s). The relative packet times may be measured by a decoder and used to calculate a centroid difference for each interval pair. The centroid differences may be used to reconstruct the watermark.
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
H04J 3/00 - Systèmes multiplex à division de temps
The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase 1/4, such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things.
This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises ( 1 ) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.
Sensitive data associations for related data values are protected. A set of related data values is received. The set of related data values include at least a first data value and a second data value. The first data value is associated with a first data field and the second data value is associated to a second data field. First encrypted data is created by encrypting the first data value using a first encryption key and a second encrypted data is created by encrypting the second data value using a second encryption key. The first data value is stored in a first data table, the second data value is stored in a second data table, the first encrypted data is stored in the second table, and the second encrypted data is stored in the first table.
Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures.
This invention relates, e.g., to a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation compared to a positive and/or negative reference standard, of one or more of: (a) AKT (S473); (b) BAD (S l 12); (c) cABL (T735); (d) ERK (T42/44); (e) MARCKS (S 152- 156); (0 p38MAPK (T l 80- 182): (g) STAT l (Y701 ); (h) PTEN (S380); (i) EGFR (Y992); (j) PAK 1 /2 (S l 19/204); or (k) PKC zeta/lambda (T410-403); or the total amount of (1) COX-2 protein; wherein if the level of phosphorylation of one or more of a-i or the total amount of COX-2 protein (1) is elevated compared to the negative reference standard, and/or i f the level of phosphorylation of j or k is decreased compared to the positive reference standard, the subject has poor prognosis, is likely to undergo metastasis, and/or is a good candidate for aggressive therapy. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing methods of the invention.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
54.
Subfemtotesla radio-frequency atomic magnetometer for nuclear quadrupole resonance detection
3) in the zero-applied field limit. Results demonstrate first time detection of NQR with an atomic magnetometer, providing that a cryogen-free atomic magnetometer, with intrinsically frequency-independent sensitivity and easy tuning capabilities, can be an attractive new tool for detecting magnetic resonance signals in the kHz to MHz range. Low intensity magnetic fields are measured using an alkali metal vapor, by increasing magnetic polarization of the vapor to increase its sensitivity, then probing the magnetic polarization of the vapor to receive an output, and determining characteristics of the low intensity magnetic field from the output.
G01V 3/00 - Prospection ou détection électrique ou magnétiqueMesure des caractéristiques du champ magnétique de la terre, p. ex. de la déclinaison ou de la déviation
Low molecular weight (LMW) peptides have been discovered that are indicative of breast cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting breast cancer and monitoring the progression of the disease, for example during treatment. The LMW peptides are particularly useful in detecting breast cancer during its early stages.
Low molecular weight (LMW) peptides have been discovered that are indicative of colorectal cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting colorectal cancer and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting colorectal cancer during its early stages.
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/483 - Analyse physique de matériau biologique
The present invention relates to methods and devices for determining the state of a neural system. In one embodiment, a plurality of stimuli to the system can be delivered to the system, and then the resulting respective responses can be analyzed to determine whether the system state is static, or whether it is undergoing dynamic changes. In another aspect of the invention, a single stimulus having a plurality of components can be administered, and the responses to each component can be contrasted and compared to determine the state of the neural system. In each case, this information can be used to predict the occurrence of neural perturbations or episodes associated with a change in the state of the neural system.
This invention relates, e.g., to a method to distinguish NASH (non-alcoholic steatohepatitis) from non-NASH types of NAFLD (non-alcoholic fatty liver disease), comprising (a) determining the phosphorylation state of one or more members of the AKT/mTOR/IRS pathway (e.g., IRS-1 (S612), AKT (S308), FKHR (T24), FKHRL (T32), GSK3 (S21/9), EIF4G (S1108), SHC (Y317), PKC-delta (T505), PKA (T197), CREB (S133), and/or FAK (Y397) in adipose tissue from a subject, wherein a significantly altered level of phosphorylation of the one or more members compared to a suitable reference standard indicates that the subject is likely to have NASH; and/or (b) determining the phosphorylation state of FAK (focal adhesion kinase) in adipose tissue from a subject, wherein a significantly increased level of phosphorylation in FAK compared to a suitable reference standard indicates that the subject is likely to have NASH. Treatment modalities based on this diagnostic method, and kits for carrying out a diagnostic method or a treatment method are also disclosed.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
A radioactive material sequestration system may include a radionuclide containment composition dispenser and a sorption based media container. The radionuclide containment composition dispenser may be configured for holding a radionuclide containment composition and be capable of dispensing the radionuclide containment composition to remove radionuclides from a radioactive material. The radionuclide containment composition is a mixture of a clay mineral and water. The sorption based media container may be configured for holding a sorption based media; receiving dispensed radionuclide containment composition; and sequestering the radionuclides. The radioactive material sequestration system may also include a probe.
HIV infection can be detected by measuring phosphorylation levels of the actin-depolymerizing factor (AFD)/cofilin family, and infection can be treated and/or prevented by modulating the HIV co-receptor signaling pathway.
C12Q 1/42 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase une phosphatase
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
61.
ELECTROSPRAY NEUTRALIZATION PROCESS AND APPARATUS FOR GENERATION OF NANO-AEROSOL AND NANO-STRUCTURED MATERIALS
The claimed invention describes methods and apparatuses for manufacturing nano- aerosols and nano-structured materials based on the neutralization of charged electrosprayed products with oppositely charged electrosprayed products. Electrosprayed products include molecular ions, nano-clusters and nano-fibers. Nano-aerosols can be generated when neutralization occurs in the gas phase. Neutralization of electrospan nano-fibers with molecular ions and charged nano-clusters may result in the formation of fibrous aerosols or free nano-mats. Nano-mats can also be produced on a suitable substrate, forming efficient nano-filters.
B01D 46/00 - Filtres ou procédés spécialement modifiés pour la séparation de particules dispersées dans des gaz ou des vapeurs
B05D 1/04 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces réalisés par pulvérisation comportant l'emploi d'un champ électrostatique
Disclosed is a Syntactic Landmine Detector. The syntactic landmine detector processes a received signal from a ground penetrating RADAR which contains at least one spatial sequence, the spatial sequence containing relative spatial information locating impedance discontinuities. The spatial sequence is then associated with at least one physical characteristic of a landmine.
G01S 13/04 - Systèmes déterminant la présence d'une cible
G01S 13/89 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation
G01V 3/12 - Prospection ou détection électrique ou magnétiqueMesure des caractéristiques du champ magnétique de la terre, p. ex. de la déclinaison ou de la déviation fonctionnant par ondes électromagnétiques
63.
EGF RECEPTOR PHOSPHORYLATION STATUS FOR DISEASE TREATMENT
This invention relates, e.g., to a method for predicting the response of a subject having a disease or condition mediated by EGFR (e.g., a cancer of epithelial origin, such as NSCLC) to an EGFR kinase inhibitor (e.g., Iressaꡞ (gefitinib) and/or Tarcevaꡞ (erlotinib)). The method comprises measuring the amount of phosphorylation at residues Y1068 and T1148 in EGFR in a sample from the subject, wherein a significantly elevated level of phosphorylation at the two residues compared to a baseline value indicates that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR. Other sites of phosphorylation that can be employed are also disclosed, including other residues in EGFR, as well as sites in other proteins of the EGFR signaling cascade.
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
64.
Link mobility tracking and its application to mobile ad hoc networks
Samsung Electronics Co., Ltd. (République de Corée)
George Mason Intellectual Properties, Inc. (USA)
Inventeur(s)
Singh, Shubhranshu
Mark, Brian
Suri, Vamit
Roh, Yong-Sung
Choi, Young-Gon
Abrégé
Embodiments of the present invention provide a method for tracking link mobility between two mobile nodes. Each node estimates a link mobility state of a link between itself and each of its neighbor nodes, accumulates successively the link mobility states, estimates link mobility parameters using the successively estimated link mobility states, and predicts a link availability probability using the link mobility parameters. The link mobility tracking can be applied to various routing protocols so as to implement mobility aware routing which enhance the routing performance.
H04L 12/28 - Réseaux de données à commutation caractérisés par la configuration des liaisons, p. ex. réseaux locaux [LAN Local Area Networks] ou réseaux étendus [WAN Wide Area Networks]
H04W 40/00 - Acheminement ou recherche d'itinéraire pour la communication
This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A watermarking system embeds a watermark into data values that may be streamed. A data hash is calculated using data values and a hash key. The data values are grouped. The groups include a first group and a second group. A first group hash is calculated using data values in the first group and a first group hash key. A second group hash is calculated using data values in the second group and a second group hash key. A watermark is constructed based on the first group hash and the second group hash. The value of at least one of the data values in the first group is modified using the watermark.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
Samsung Electronics Co., Ltd. (République de Corée)
George Mason Intellectual Properties, Inc. (USA)
Inventeur(s)
Singh, Shubhranshu
Roh, Yong-Sung
Kim, Jae-Hoon
Kang, Kyung-Lim
Choi, Young-Gon
Kim, Jung-Ho
Mark, Brian L.
Abrégé
An ad-hoc network and routing method that takes account of mobility are provided. The ad-hoc network includes at least one node, which calculates a probability that a neighbor node is present in a transmission range of the node, generates a message containing the calculated probability, and transmits the message to the neighbor node. The at least one node may also update the message with a lower probability of the calculated probability and a probability contained in the message, and transmit the updated message to the neighbor node. The node may also determine as a route a path along which a message is transmitted from the message containing the highest probability among probabilities contained in messages that are received.
H04W 40/00 - Acheminement ou recherche d'itinéraire pour la communication
H04B 7/00 - Systèmes de transmission radio, c.-à-d. utilisant un champ de rayonnement
H04L 12/26 - Dispositions de surveillance; Dispositions de test
H04L 12/28 - Réseaux de données à commutation caractérisés par la configuration des liaisons, p. ex. réseaux locaux [LAN Local Area Networks] ou réseaux étendus [WAN Wide Area Networks]
69.
SCIT-DNS: critical infrastructure protection through secure DNS server dynamic updates
Disclosed is a self-cleansing intrusion tolerance-domain name systems system comprising at least three DNS servers, at least four storage systems accessible by the DNS servers, a communications link, a message transfer mechanism, and a self-cleansing mechanism. The storage systems include at least three online storage systems and at least one offline storage system. The communications link can connect the DNS servers with the storage systems, as well as connect the DNS servers with a local area network, which can connect the DNS servers with an external network. The message transfer mechanism can rotate the DNS servers into a plurality of roles, including a primary role, a secondary role, a designated role, and a self-cleansing role. The self-cleansing mechanism can be used to perform the self-cleansing role.
G06F 15/16 - Associations de plusieurs calculateurs numériques comportant chacun au moins une unité arithmétique, une unité programme et un registre, p. ex. pour le traitement simultané de plusieurs programmes
70.
Interactive closed-loop data entry with real-time graphical feedback
Disclosed is an interactive closed loop data entry mechanism with real-time graphical feedback. The mechanism includes a spatial display processor, a graphical feedback mechanism, an entry interface, a value updater, and a connected-system-interface.
Disclosed is a fragile watermarking scheme for detecting and localizing malicious alterations made to a database relation with categorical attributes without introducing distortions to cover data. A watermark for a tuple group may be inserted by selectively switching the position of tuples in tuple pairs using a tuple hash associated with each tuple in the tuple pair; and a corresponding bit in a watermark derived from the tuple group using a embedding key, a primary key and hash functions.
Disclosed is a Syntactic Landmine Detector. The syntactic landmine detector processes a received signal from a ground penetrating RADAR which contains at least one spatial sequence, the spatial sequence containing relative spatial information locating impedance discontinuities. The spatial sequence is then associated with at least one physical characteristic of a landmine.
Disclosed is a network hardening mechanism. The mechanism: generates a dependency graph from a multitude of exploits; constructs a goal conditions expression which may then be used to determine set(s) of safe network configurations. A subset of these safe network configuration sets may then be selected for implementation using hardening costs as a criterion.
G06F 12/14 - Protection contre l'utilisation non autorisée de mémoire
G06F 7/04 - Contrôle d'égalité, c.-à-d. pour valeurs égales ou non
G06F 15/173 - Communication entre processeurs utilisant un réseau d'interconnexion, p. ex. matriciel, de réarrangement, pyramidal, en étoile ou ramifié
An episode classification system including a multitude of diagnosis records. Each of the diagnosis records includes diagnoses information, time of diagnoses information, and patient information. A patient grouper generates at least one patient group by grouping patient records having similar patient information. A diagnosis grouper generates at least one diagnosis group from a patient group by grouping patient records from a patient group that have similar diagnosis information. An episode analyzer includes a probability analyzer, an episode grouper, and a severity analyzer. The probability analyzer performs probability calculations capable of generating a probability value using at least two of the diagnosis records as input entries. The probability value represents the probability that the input entries belong to a single episode. The episode grouper groups diagnosis records determined to belong to a single episode. The severity analyzer performs episode severity calculations capable of generating an episode severity value.
G06Q 50/00 - Technologies de l’information et de la communication [TIC] spécialement adaptées à la mise en œuvre des procédés d’affaires d’un secteur particulier d’activité économique, p. ex. aux services d’utilité publique ou au tourisme
brevets
